[Complex therapy for non-melanotic skin cancers in the head and neck region]

Although most malignant non-melanoma skin cancers are low-risk and curable with surgical intervention, the management of locally advanced and metastasizing tumors is very challenging. Previous systemic treatment options for advanced skin cancer were limited to cytotoxic chemotherapy and anti-epidermal growth factor receptor (EGFR) therapy, with significant morbidity and poor durable response rates, but the newly emerged therapies such as Hedgehog pathway inhibitors and immunotherapies have improved not only the survival, but the patients' quality of life too. The clinical trials of neoadjuvant immunotherapies are still ongoing, but in the case of borderline resection margins or surgical removal with high morbidity or severe functional impairment, immunotherapy can be a good option for aesthetical and functional preservation and provides a long term survival with combination of oncological therapies.